Explore the vast range of titles available.

The automobile industry no longer relies on pure mechanical systems; instead, it benefits from many smart features based on advanced embedded electronics. Although the rise in electronics and connectivity has improved comfort, functionality, and safe driving, it has also created new attack surfaces to penetrate the in-vehicle communication network, which was initially designed as a close loop system. For such applications, the Controller Area Network (CAN) is the most-widely used communication protocol, which still suffers from various security issues because of the lack of encryption and authentication. As a result, any malicious/hijacked node can cause catastrophic accidents and financial loss. This paper analyses the CAN bus comprehensively to provide an outlook on security concerns. It also presents the security vulnerabilities of the CAN and a state-of-the-art attack surface with cases of implemented attack scenarios and goes through different solutions that assist in attack prevention, mainly based on an intrusion detection system (IDS).

In the current arena, new-generation functional nanomaterials are the key players for smart solutions and applications including environmental decontamination of pollutants. Among the plethora of new-generation nanomaterials, graphene-based nanomaterials and nanocomposites are in the driving seat surpassing their counterparts due to their unique physicochemical characteristics and superior surface chemistry. The purpose of the present research was to synthesize and characterize magnetite iron oxide/reduced graphene oxide nanocomposites (FeNPs/rGO) via a green approach and test its application in the degradation of methylene blue. The modified Hummer's protocol was adopted to synthesize graphene oxide (GO) through a chemical exfoliation approach using a graphitic route. Leaf extract of Azadirachta indica was used as a green reducing agent to reduce GO into reduced graphene oxide (rGO). Then, using the green deposition approach and Azadirachta indica leaf extract, a nanocomposite comprising magnetite iron oxides and reduced graphene oxide i.e., FeNPs/rGO was synthesized. During the synthesis of functionalized FeNPs/rGO, Azadirachta indica leaf extract acted as a reducing, capping, and stabilizing agent. The final synthesized materials were characterized and analyzed using an array of techniques such as scanning electron microscopy (SEM)-energy dispersive X-ray microanalysis (EDX), Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction analysis, and UV–visible spectrophotometry. The UV–visible spectrum was used to evaluate the optical characteristics and band gap. Using the FT-IR spectrum, functional groupings were identified in the synthesized graphene-based nanomaterials and nanocomposites. The morphology and elemental analysis of nanomaterials and nanocomposites synthesized via the green deposition process were investigated using SEM–EDX. The GO, rGO, FeNPs, and FeNPs/rGO showed maximum absorption at 232, 265, 395, and 405 nm, respectively. FTIR spectrum showed different functional groups (OH, COOH, C=O), C–O–C) modifying material surfaces. Based on Debye Sherrer's equation, the mean calculated particle size of all synthesized materials was < 100 nm (GO = 60–80, rGO = 90–95, FeNPs = 70–90, Fe/GO = 40–60, and Fe/rGO = 80–85 nm). Graphene-based nanomaterials displayed rough surfaces with clustered and spherical shapes and EDX analysis confirmed the presence of both iron and oxygen in all the nanocomposites. The final nanocomposites produced via the synthetic process degraded approximately 74% of methylene blue. Based on the results, it is plausible to conclude that synthesized FeNPs/rGO nanocomposites can also be used as a potential photocatalyst degrader for other different dye pollutants due to their lower band gap.

Early diagnosis of malignant spinal cord compression (SCC) is crucial because pretreatment neurological status is the major determinant of outcome. In metastatic castration-resistant prostate cancer, SCC is a clinically significant cause of disease-related morbidity and mortality. We investigated whether screening for SCC with spinal MRI, and pre-emptive treatment if radiological SCC (rSCC) was detected, reduced the incidence of clinical SCC (cSCC) in asymptomatic patients with metastatic castration-resistant prostate cancer and spinal metastasis. We did a parallel-group, open-label, randomised, controlled, phase 3, superiority trial. Patients with metastatic castration-resistant prostate cancer were recruited from 45 National Health Service hospitals in the UK. Eligible patients were aged at least 18 years, with an Eastern Co-operative Oncology Group performance status of 0–2, asymptomatic spinal metastasis, no previous SCC, and no spinal MRI in the past 12 months. Participants were randomly assigned (1:1), using a minimisation algorithm with a random element (balancing factors were treatment centre, alkaline phosphatase [normal vs raised, with the upper limit of normal being defined at each participating laboratory], number of previous systemic treatments [first-line vs second-line or later], previous spinal treatment, and imaging of thorax and abdomen), to no MRI (control group) or screening spinal MRI (intervention group). Serious adverse events were monitored in the 24 h after screening MRI in the intervention group. Participants with screen-detected rSCC were offered pre-emptive treatment (radiotherapy or surgical decompression was recommended per treating physician's recommendation) and 6-monthly spinal MRI. All patients were followed up every 3 months, and then at month 30 and 36. The primary endpoint was time to and incidence of confirmed cSCC in the intention-to-treat population (defined as all patients randomly assigned), with the primary timepoint of interest being 1 year after randomisation. The study is registered with ISRCTN, ISRCTN74112318, and is now complete. Between Feb 26, 2013, and April 25, 2017, 420 patients were randomly assigned to the control (n=210) or screening MRI (n=210) groups. Median age was 74 years (IQR 68 to 79), 222 (53%) of 420 patients had normal alkaline phosphatase, and median prostate-specific antigen concentration was 48 ng/mL (IQR 17 to 162). Screening MRI detected rSCC in 61 (31%) of 200 patients with assessable scans in the intervention group. As of data cutoff (April 23, 2020), at a median follow-up of 22 months (IQR 13 to 31), time to cSCC was not significantly improved with screening (hazard ratio 0·64 [95% CI 0·37 to 1·11]; Gray's test p=0·12). 1-year cSCC rates were 6·7% (95% CI 3·8–10·6; 14 of 210 patients) for the control group and 4·3% (2·1–7·7; nine of 210 patients) for the intervention group (difference −2·4% [95% CI −4·2 to 0·1]). Median time to cSCC was not reached in either group. No serious adverse events were reported within 24 h of screening. Despite the substantial incidence of rSCC detected in the intervention group, the rate of cSCC in both groups was low at a median of 22 months of follow-up. Routine use of screening MRI and pre-emptive treatment to prevent cSCC is not warranted in patients with asymptomatic castration-resistant prostate cancer with spinal metastasis. Cancer Research UK.

The use of a polygenic risk score to screen for prostate cancer was assessed. Of the 468 persons in at least the 90th percentile of genetic risk who underwent MRI and prostate biopsy, 187 (40.0%) had prostate cancer.

Multiple categories of electronic devices have been introduced recently in response to the demands and developments in the industry. Around 5.19 billion telecom services subscribers today have a significant effect on the allocation and utilization of bandwidth, and hence, there is extensive need to use higher-frequency bands, e.g., mm band to achieve the required quality of service since there is extensive need to shift the paradigm to the next generation. For 5G networks, antenna structuring and designing is an integral part of the communication system. In antenna theory, improving antenna gain is important to attain isotropic antenna, antenna gain can be improved by the controlled behavior of frequencies, beam forming and choosing the right antenna fabric. Through antenna design using different substrates thickness, the propagation losses are examined in order to determine the variation with radiation characteristics. In this way, the examination of the 5G mm-wave spectrum with comparative analysis of input impedance, gain and radiation efficiency is shown through mathematical modeling. Using this approach, the antenna efficiency is improved by up to 20% with increase in substrate thickness. Different antenna arrays have been designed for effective improvement in reflection coefficients. The results are obtained using simulation of antenna in CST and high-frequency structure simulator.

Constitutional or germline pathogenic variants (GPVs) in protection of telomeres 1 (POT1) are associated with a variety of tumours resulting in the recognition of POT1-tumour predisposition syndrome (POT1-TPDS). These tumours may include cutaneous melanoma, angiosarcoma, haematological malignancy and brain tumours. Due to the rarity of POT1 GPVs and limited available data, the overall lifetime cancer risks for individuals with POT1-TPDS are unclear. Furthermore, there is scant evidence to support the role of surveillance in early cancer detection in this patient group. A recent international publication suggested a surveillance protocol similar to that used in Li-Fraumeni Syndrome (LFS) could be offered to POT1 pathogenic variant carriers, particularly where there are LFS-like features. However, current evidence for POT1-TPDS is not supportive of an equivalent lifetime cancer risk. Given the inclusion of POT1 in the National Test Directory in England and the need for UK-based guidance, an expert group undertook a literature review to assess the phenotypic spectrum of POT1-TPDS and to provide lifetime risk estimates of POT1-associated cancers. The available evidence was shared with a small working group of experts that included clinical geneticists, dermatologists, sarcoma specialists, haematologists and radiologists to cover all aspects of the cancers most commonly associated with POT1-TPDS. Following structured expert group discussions, we achieved consensus on best practice recommendations for a POT1-TPDS UK management protocol.

Constitutional pathogenic variants in TP53 are associated with Li-Fraumeni syndrome or the more recently described heritable TP53-related cancer syndrome and are associated with increased lifetime risks of a wide spectrum of cancers. Due to the broad tumour spectrum, surveillance for this patient group has been limited. To date, the only recommendation in the UK has been for annual breast MRI in women; however, more recently, a more intensive surveillance protocol including whole-body MRI (WB-MRI) has been recommended by International Expert Groups. To address the gap in surveillance for this patient group in the UK, the UK Cancer Genetics Group facilitated a 1-day consensus meeting to discuss a protocol for the UK. Using a preworkshop survey followed by structured discussion on the day, we achieved consensus for a UK surveillance protocol for TP53 carriers to be adopted by UK Clinical Genetics services. The key recommendations are for annual WB-MRI and dedicated brain MRI from birth, annual breast MRI from 20 years in women and three-four monthly abdominal ultrasound in children along with review in a dedicated clinic.

BackgroundGermline TP53 gene pathogenic variants (pv) cause a very high lifetime risk of developing cancer, almost 100% for women and 75% for men. In the UK, annual MRI breast screening is recommended for female TP53 pv carriers. The SIGNIFY study (Magnetic Resonance Imaging screening in Li Fraumeni syndrome: An exploratory whole body MRI) study reported outcomes of whole-body MRI (WB-MRI) in a cohort of 44 TP53 pv carriers and 44 matched population controls. The results supported the use of a baseline WB-MRI screen in all adult TP53 pv carriers. Here we report the acceptability of WB-MRI screening and effects on psychosocial functioning and health-related quality of life in the short and medium terms.MethodsPsychosocial and other assessments were carried out at study enrolment, immediately before MRI, before and after MRI results, and at 12, 26 and 52 weeks’ follow-up.ResultsWB-MRI was found to be acceptable with high levels of satisfaction and low levels of psychological morbidity throughout. Although their mean levels of cancer worry were not high, carriers had significantly more cancer worry at most time-points than controls. They also reported significantly more clinically significant intrusive and avoidant thoughts about cancer than controls at all time-points. There were no clinically significant adverse psychosocial outcomes in either carriers with a history of cancer or in those requiring further investigations.ConclusionWB-MRI screening can be implemented in TP53 pv carriers without adverse psychosocial outcomes in the short and medium terms. A previous cancer diagnosis may predict a better psychosocial outcome. Some carriers seriously underestimate their risk of cancer. Carriers of pv should have access to a clinician to help them develop adaptive strategies to cope with cancer-related concerns and respond to clinically significant depression and/or anxiety.

Graphene-based nanomaterials have been proved to be robust sorbents for efficient removal of environmental contaminants including arsenic (As). Biobased graphene oxide (bGO-P) derived from sugarcane bagasse via pyrolysis, GO-C via chemical exfoliation, and magnetite nanoparticles (FeNPs) via green approach using Azadirachta indica leaf extract were synthesized and characterized by Ultraviolet-Visible Spectrophotometer (UV-vis.), Fourier transform infrared (FTIR) spectroscopy, X-ray diffraction (XRD), mean particle size and Scanning electron microscopy (SEM) along with Energy dispersive spectroscopy (EDX) analysis. Compared to cellulose and hemicellulose, the lignin fraction was less in the precursor material. The GOC, bGO-P and FeNPs displayed maximum absorption at 230, 236, and 374 nm, respectively. FTIR spectrum showed different functional groups (C-OH, C-O-C, COOH and O-H) modifying the surfaces of synthesized materials. Graphene based nanomaterials showed clustered dense flakes of GO-C and thin transparent flakes of bGO-P. Elemental composition by EDX analysis of GO-C (71.26% C and 27.36% O), bGO-P (74.54% C and 24.61% O) and FeNPs (55.61% Fe, 4.1% C and 35.72% O) confirmed the presence of carbon, oxygen, and iron in synthesized nanomaterials. Sorption study was conducted with soil amended with different doses of synthesized nanomaterials (10, 50 and 250 mg) and exposed to 100, 300 and 500 ppm of As. Arsenic concentrations were estimated by colorimetry and atomic absorption spectroscopy (AAS). GO-C, bGO-P, and FeNPs showed substantial As removal efficiency i.e., 81 to 99.3%, 65 to 98.8% and 73.1–89.9%, respectively. Green synthesis of bGO-P and magnetite nanoparticles removed substantial amounts of As compared to GO-C and can be effectively deployed for As removal or immobilization. Higher and medium sorbent doses (250 and 50 mg) exhibited greater As removal and data was best fitted for Freundlich isotherm evidencing favorable sorption. Nevertheless, at low sorbent doses, data was best fitted for both models. Newly synthesized nanomaterials emerged as promising materials for As removal strategy for soil nano-remediation and can be effectively deployed in As contaminated soils.

Introduction/BackgroundThe prevalence of incidental adrenal nodules is 4%. Although the majority of incidental adrenal nodules are benign (85%) and non-functional, malignant and hormone-secreting nodules (excess cortisol, aldosterone or catecholamines) require timely investigation and management. Currently, there is limited literature on their management in the pre-operative oncology setting and further investigation is time consuming and often causes significant delays to the planned gynaecological oncology surgical treatment.MethodologyRetrospective single cohort observational study undertaken at a tertiary cancer centre in UK. Patients undergoing major gynaecology oncology surgery who had incidental adrenal pathology reported on pre-operative imaging over a one year period (July 2019 – July 2020) were identified. Patient demographics, endocrine investigations and delays in treatment pathways were reported using descriptive statistics.ResultsIncidental finding of adrenal pathology were reported in 9 of the 346 cases (2.6%). Patient age ranged from 30–73 years old. The primary sites of malignancy included ovarian (4/9), endometrial (4/9) and cervical (1/9). All adrenal pathology was identified on preoperative CT; the reports did not categorise these into benign or malignant/functioning. The size of the adrenal pathologies ranged from 11 mm – 70 mm (median = 26 mm). PET CT was used to further evaluate an adrenal nodule (1/9).In those cases that had further investigations, initial tests included both urinary and plasma metanephrines 1/9, plasma metanephrines (2/9) and urinary metanephrines (5/9). Additional tests were undertaken in two cases; a dexamethasone suppression test (1/9) and serum renin/aldosterone (2/9). From these, 2/9 had abnormal urinary metanephrines. 1/9 was a false positive result and the other had endocrinology review for a raised methotyramine only which was not felt to be clinically significant. An adrenal malignancy or phaemochromocytoma was not identified within the cohort. (2/9) had no investigations or endocrinology input. The planned gynaecological surgical date was postponed in 4/9 cases to allow for investigation of the adrenal pathology to rule out a functioning or malignant lesion. The delay to surgery ranged 0–56 days (median 21 days). There was no progression of disease or change to the original management plan as a result of the delay.ConclusionThere is heterogeneity in the investigation and management of incidental adrenal pathology and significant delays to the surgical treatment of the patients’ primary gynaecology malignancy. We recommend adopting the European Society of Endocrinology guidelines to develop a local pathway with input from our endocrinology and radiology colleagues to ensure these patients are investigated in a timely and standardised manner and avoid undue delays to surgical treatment for the patient’s gynaecological malignancy.DisclosuresNone of the authors wish to disclose any potential conflict of interest.